BR112017000520A2 - composto ou sal do mesmo, uso um composto ou de um sal, e, kit. - Google Patents

composto ou sal do mesmo, uso um composto ou de um sal, e, kit.

Info

Publication number
BR112017000520A2
BR112017000520A2 BR112017000520A BR112017000520A BR112017000520A2 BR 112017000520 A2 BR112017000520 A2 BR 112017000520A2 BR 112017000520 A BR112017000520 A BR 112017000520A BR 112017000520 A BR112017000520 A BR 112017000520A BR 112017000520 A2 BR112017000520 A2 BR 112017000520A2
Authority
BR
Brazil
Prior art keywords
salt
compound
kit
treatments
salts
Prior art date
Application number
BR112017000520A
Other languages
English (en)
Inventor
Regina Heckeroth Anja
Pierre Alain Chassaing Christophe
Lutz Jürgem
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112017000520A2 publication Critical patent/BR112017000520A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

esta invenção está relacionada aos compostos e sais que são, de modo geral, úteis como agentes para tratar uma infecção causada por dirofilaria immitis. esta invenção refere-se, também, aos tratamentos compreendendo a administração dos compostos e sais aos animais que necessitam dos tratamentos.
BR112017000520A 2014-07-11 2015-07-10 composto ou sal do mesmo, uso um composto ou de um sal, e, kit. BR112017000520A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14176737 2014-07-11
PCT/EP2015/065870 WO2016005577A1 (en) 2014-07-11 2015-07-10 Use of anthelmintic agents against dirofilaria immitis

Publications (1)

Publication Number Publication Date
BR112017000520A2 true BR112017000520A2 (pt) 2017-11-14

Family

ID=51167759

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000520A BR112017000520A2 (pt) 2014-07-11 2015-07-10 composto ou sal do mesmo, uso um composto ou de um sal, e, kit.

Country Status (7)

Country Link
US (1) US20170196854A1 (pt)
EP (1) EP3166605A1 (pt)
JP (1) JP2017519801A (pt)
CN (1) CN106470683A (pt)
AU (1) AU2015286635A1 (pt)
BR (1) BR112017000520A2 (pt)
WO (1) WO2016005577A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018240172C1 (en) 2017-03-20 2019-10-24 Novo Nordisk Health Care Ag Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
JOP20190223A1 (ar) 2017-04-01 2019-09-26 Novartis Ag عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3980414A1 (en) * 2019-06-07 2022-04-13 Elanco Tiergesundheit AG Bicyclic derivatives for treating endoparasites
EP4110336A4 (en) 2020-02-28 2024-06-05 Auburn University SIGNATURES OF DIROFILARIA VOLATILE ORGANIC COMPOUNDS AND THEIR USES
CN113354660B (zh) * 2020-03-06 2024-04-23 广州再极医药科技有限公司 噻吩并嘧啶类衍生物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200938203A (en) * 2007-12-17 2009-09-16 Intervet Int Bv Anthelmintic agents and their use
TW201041868A (en) * 2009-03-20 2010-12-01 Intervet Int Bv Anthelmintic agents and their use
TW201111358A (en) * 2009-06-18 2011-04-01 Intervet Int Bv Anthelmintic agents and their use
EP2468096A1 (en) * 2010-12-21 2012-06-27 Intervet International BV Anthelmintic combinations
WO2014081697A2 (en) * 2012-11-20 2014-05-30 Merial Limited Anthelmintic compounds and compositions and method of using thereof

Also Published As

Publication number Publication date
EP3166605A1 (en) 2017-05-17
AU2015286635A1 (en) 2017-01-19
WO2016005577A1 (en) 2016-01-14
JP2017519801A (ja) 2017-07-20
CN106470683A (zh) 2017-03-01
US20170196854A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
BR112017000520A2 (pt) composto ou sal do mesmo, uso um composto ou de um sal, e, kit.
BR112017000398A2 (pt) composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit.
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CO2017005995A2 (es) Composiciones para el cuidado bucal y métodos de uso
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
BR112018007664A2 (pt) antagonistas de ep4
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
EA201791140A1 (ru) Противомикробные составы и соответствующие методы обработки пищевых продуктов и поверхностей
BR112017008496A2 (pt) compostos para uso em tratamento antelmíntico
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
EA201790091A1 (ru) Лечение тяжелой гипертриглицеридемии
EA201792123A1 (ru) Лечение боли
BR112017005272A2 (pt) uso de cisteamina no tratamento de infecções causadas por leveduras/bolores
BR112017003231A2 (pt) compostos heterobicíclicos e seu uso para o tratamento da tuberculose
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]